Diagnostic Value of Noninvasive Diagnostic Model of Liver Fibrosis in Combination with Serum Hyaluronic Acid in Patients with Chronic Hepatitis B

Chihong WU,Gengshan TIAN,Xiooyuan XU,Yanyan YU,Hailing LU
DOI: https://doi.org/10.3969/j.issn.1008-7125.2008.06.002
2008-01-01
Abstract:Background: Although liver biopsy remains the gold standard for the diagnosis of liver fibrosis, there are still limitations in its clinical application. Aims: To assess the diagnostic value of Fibromodel (a noninvasive diagnostic model of liver fibrosis) in combination with hyaluronic acid (HA, a serum fibrotic marker) in patients with chronic hepatitis B (CHB). Methods: One hundred and thirty CHB patients were enrolled. Liver biopsy specimens were collected to assess the stage of fibrosis histologically. ≥S2 was defined as significant fibrosis, and S4 as early cirrhosis. The related laboratory markers were determined simultaneously. Receiver operating characteristic (ROC) curve was used to analyze the diagnostic value of Fibromodel and serum HA, and the combination method was evaluated by positive predictive value (PPV) and negative predictive value (NPV). Results: The area under curve (AUC) of Fibromodel for ≥S2 was 0.792. When the cut off value was set at 0.15, the sensitivity, specificity and NPV for exclusion of significant fibrosis were 81.1%, 62.4% and 87.5%, respectively; when the cut off value was set at 0.5, the sensitivity, specificity and PPV for diagnosis of significant fibrosis were 68.1%, 76.9% and 64.2%, respectively. Biopsies being done in patients with Fibromodel value 0.15-0.5 would reduce the need for liver biopsy by 46.2% with an accuracy rate of 76.7%. The AUC of serum HA for ≥S2 was 0.789. When the cut off value was set at 60 ng/ml, the sensitivity, specificity and NPV were 76.8%, 78.2% and 82.9%, respectively. The AUC of serum HA for S4 was 0.801. When the cut off value was set at 140 ng/ml, the sensitivity, specificity and PPV were 85.5%, 81.6% and 82.1%, respectively. If patients unidentified by Fibromodel were assessed by serum HA, the need for liver biopsy would reduce by 60.0% with an accuracy rate of 83.3%. Conclusions: A combination of Fibromodel with serum HA improves the diagnostic performance for liver fibrosis in CHB patients and may partially replace the liver biopsy.
What problem does this paper attempt to address?